ThromboGenics reports €6 million in revenues in first half

ThromboGenics reported 6 million in total revenues for the first half of 2015, according to a press release.This includes 4.25 million in Jetrea (ocriplasmin) sales in the U.S. and 1.75 million in Alcon royalties from Jetrea sales outside the U.S. compared with 5 million and 1.7 million, respectively, in the first half of 2014.